Navigation Links
China Cord Blood Corporation Announces Results for the Quarter and Six Months Ended September 30, 2009
Date:12/11/2009
3,047 (12,260) Pro forma adjustments: Income attributable to redeemable non- controlling interests 347 -- 347 -- Write-off of deferred reverse recapital- ization costs -- -- 21,566 -- Non-GAAP net income attributable to China Cord Blood Corporation shareholders 17,986 5,779 34,960 (12,260) DENOMINATOR ('000 shares) Weighted average ordinary shares issued and outstanding 61,143 43,237 52,190 43,237 Pro forma adjustments: Issue of ordinary shares upon share exchange with ordinary shareholders of China Cord Blood Services Corporation in June 2009 -- 12,476 6,238 12,476 Issue of ordinary shares upon share exchange with redeemable ordinary shareholders of China Cord Blood Services Corporation in August 2009 1,650 3,506 2,578 3,506 Pro forma weighted average ordinary shares issued and outstanding 62,793 59,219 61,006 59,219 Non-GAAP basic income/ (loss) per share attributable to China Cord Blood Corporation shareholders (RMB) 0.29 0.10 0.57 (0.21) Non-GAAP basic income attributable to shareholders (US$) 0.04 0.08
SOURCE China Cord Blood Corporation
'/>"/>
| SOURCE China Cord Blood Corporation Copyright©2009 PR Newswire. All rights reserved |
Related medicine news :
1. China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009
2. Moravia Worldwide to Participate in the 5th EU-China Business Summit 2009 in Nanjing China
3. ESC to give talks on diabetes in 3 cities in China
4. China Medical Technologies Reports Second Fiscal Quarter Financial Results
5. China Shenghuo Reports Unaudited Financial Results for the Third Quarter of 2009
6. Jiangbo Pharmaceuticals to Present at Brean Murray, Carret 2009 China Growth Conference
7. Novartis to Acquire Majority Stake in Hard to Treat Diseases (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million
8. Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin
9. HUYA Bioscience International Establishes Strategic Partnership with School of Medicine and Pharmacy, Ocean University of China
10. China Nepstar Enters Into Strategic Cooperation Agreement with ATMU to Install More Than 1,000 ATMs in Nepstar Stores
11. China Medical Technologies to Announce Unaudited Financial Results for the Second Fiscal Quarter Ended September 30, 2009 on November 19, 2009
Post Your Comments:
(Date:5/21/2013)... May 21, 2013 Two executives from ... (SBG) will identify which strategies can be most effective ... care to the members who are taking them, in ... Inc., “How to Manage Specialty Drugs to Reduce ... are now the main driver for rising prescription drug ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The American ... million people in the United States of America are ... are at a great risk of developing peripheral neuropathy ... normal lives. The ADA further goes on saying that ... years and around 2 million new cases are diagnosed ...
(Date:5/21/2013)... HealthDay Reporter , , TUESDAY, May 21 (HealthDay ... steroid therapy for patients having severe bouts of chronic ... Five days of glucocorticoid treatment with prednisone to treat ... days, but with fewer chances for adverse side effects, ... shorter period of treatment was not less effective than ...
(Date:5/21/2013)... that it is a Grand Challenges Explorations winner, ... Gates Foundation. Tae Seok Moon, PhD, assistant professor ... an innovative global health and development research project ... Organisms." , Grand Challenges Explorations (GCE) funds individuals ... mold in how we solve persistent global health ...
(Date:5/21/2013)... As many as 35 percent of Mexican young adults ... University of Illinois scientist who conducted a study at ... students who inherited genetic risk factors from both parents ... around the waist than those who hadn,t. They also ... a U of I professor of food science and ...
Breaking Medicine News(10 mins):Health News:Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar 2Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 2Health News:COPD Patients May Do Fine With Shorter Course of Steroids 3Health News:Gates Fellowship addresses parasite infection in developing world 2Health News:Genetic risk for obesity found in many Mexican young adults 2[0] Consulting Firm Execs to Discuss Strategies for Effective Management of Specialty Drugs in AIS’s May 30 Webinar[0] Neuracel Aims to Reduce Peripheral Neuropathy Pain[0] COPD Patients May Do Fine With Shorter Course of Steroids[0] Gates Fellowship addresses parasite infection in developing world[0] Genetic risk for obesity found in many Mexican young adults
... 24 (HealthDay News) -- Morbidly obese patients who undergo spinal ... and also face higher hospital costs, a new study says. ... spinal pain. People with a body mass index (BMI) of ... generally 50 to 100 percent over their ideal body weight, ...
... , WEDNESDAY, May 23 (HealthDay News) -- The risk of ... travel more slowly through the lower chambers of the heart, ... heart and cause it to pump blood through its four ... be measured using an electrocardiogram (ECG). The waves traveling through ...
... the most comprehensive analyses to date of the cost of ... that this now-dominant surgical approach is significantly more costly than ... patient outcomes. The results of the study are available online ... Urology . In one of the first ...
... that maintain healthy nerve connections as we age help keep ... charity Age UK has found. Older people with robust ... different, distant brain areas can process information quickly and ... According to the findings, joining distant parts of the ...
... , WEDNESDAY, May 23 (HealthDay News) -- The ... reduced through a multi-pronged approach that includes more training ... to a new German study. Despite legal regulations ... as bed rails and belts still are frequently used ...
... Minn. -- Mayo Clinic researchers will present findings on ... at the annual meeting of the American Urological Association ... be available to provide expert comment for reporters covering ... presented and their embargo dates include: No ...
Cached Medicine News:Health News:Severely Obese Have More Complications With Spinal Surgery 2Health News:Study Spots Early Warning Signal for Sudden Cardiac Death 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 3Health News:Well-connected brains make you smarter in older age 2Health News:Study Offers Ways to Decrease Use of Restraints at Nursing Homes 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Severely Obese Have More Complications With Spinal SurgeryStudy Spots Early Warning Signal for Sudden Cardiac DeathRobotic-assisted prostate cancer surgery drives up costs, UPMC study findsWell-connected brains make you smarter in older ageStudy Offers Ways to Decrease Use of Restraints at Nursing HomesMayo Clinic urologists present findings at American Urological Association Annual Meeting
(Date:5/21/2013)... , May 21, 2013 Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
(Date:5/21/2013)... 2013 BioRestorative Therapies, Inc. ("BRT" or the "Company") ... developing stem cell based therapies for various personal applications, ... President and CEO, will be presenting at the Marcum ... held on Thursday, May 30, 2013 at the Grand ... New York City. Mr. Weinreb,s presentation will take place ...
(Date:5/21/2013)... , May 21, 2013 STAAR Surgical Company ... and marketer of minimally invasive ophthalmic products, today announced ... to review the Company,s recent financial results and business ... Surgical will present at the 38 th Annual ... at the Westin Waterfront Hotel on Wednesday, ...
Breaking Medicine Technology:Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3STAAR Surgical To Present At Upcoming Investor Conferences 2[0] Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients[0] BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference[0] STAAR Surgical To Present At Upcoming Investor Conferences
... from Cytel join peers in examining the rise of ... ... CAMBRIDGE, Mass., June 23 Cytel,s renowned adaptive,trial design and implementation ... will lead workshops and case,study reviews at the Annual Meeting of ...
... 23 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... Phase 2a clinical trial of Staccato(R) loxapine (AZ-104) ... Annual Scientific Meeting of,the American Headache Society, which ... Boston, MA. The oral platform abstract presentation,"Inhaled Loxapine, ...
Cached Medicine Technology:Cytel's Clinical Innovation Experts Cyrus Mehta and Judith Quinlan Reveal Latest Adaptive Trial Successes at 44th Annual DIA Meeting 2Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting 2The Natural-Knee Family is a complete range of interchangeable, anatomically-designed implants with over 14 years of proven clinical results....
Maximum contact. Minimum wear. Outstanding results....
...
...
Medicine Products:| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |